Breast-Cancer Risk in Families with Mutations in PALB2 AC Antoniou, S Casadei, T Heikkinen, D Barrowdale, K Pylkäs, J Roberts, ... New England Journal of Medicine 371 (6), 497-506, 2014 | 1079 | 2014 |
Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis P Savas, B Virassamy, C Ye, A Salim, CP Mintoff, F Caramia, R Salgado, ... Nature medicine 24 (7), 986-993, 2018 | 834 | 2018 |
Macrophage-derived CXCL9 and CXCL10 are required for antitumor immune responses following immune checkpoint blockade IG House, P Savas, J Lai, AXY Chen, AJ Oliver, ZL Teo, KL Todd, ... Clinical Cancer Research 26 (2), 487-504, 2020 | 428 | 2020 |
Relevance of tumor-infiltrating lymphocytes in breast cancer S Dushyanthen, PA Beavis, P Savas, ZL Teo, C Zhou, M Mansour, ... BMC medicine 13, 1-13, 2015 | 259 | 2015 |
PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS MC Southey, DE Goldgar, R Winqvist, K Pylkäs, F Couch, M Tischkowitz, ... Journal of medical genetics 53 (12), 800-811, 2016 | 241 | 2016 |
Combined CDK4/6 and PI3Kα inhibition is synergistic and immunogenic in triple-negative breast cancer ZL Teo, S Versaci, S Dushyanthen, F Caramia, P Savas, CP Mintoff, ... Cancer research 77 (22), 6340-6352, 2017 | 175 | 2017 |
The subclonal architecture of metastatic breast cancer: results from a prospective community-based rapid autopsy program “CASCADE” P Savas, ZL Teo, C Lefevre, C Flensburg, F Caramia, K Alsop, M Mansour, ... PLoS medicine 13 (12), e1002204, 2016 | 147 | 2016 |
A PALB2 mutation associated with high risk of breast cancer MC Southey, ZL Teo, JG Dowty, FA Odefrey, DJ Park, M Tischkowitz, ... Breast Cancer Research 12, 1-10, 2010 | 147 | 2010 |
Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancer S Dushyanthen, ZL Teo, F Caramia, P Savas, CP Mintoff, B Virassamy, ... Nature communications 8 (1), 606, 2017 | 105 | 2017 |
A community-based model of rapid autopsy in end-stage cancer patients K Alsop, H Thorne, S Sandhu, A Hamilton, C Mintoff, E Christie, O Spruyt, ... Nature biotechnology 34 (10), 1010-1014, 2016 | 86 | 2016 |
PALB2 and breast cancer: ready for clinical translation! MC Southey, ZL Teo, I Winship The application of clinical genetics, 43-52, 2013 | 62 | 2013 |
Rare Mutations in RINT1 Predispose Carriers to Breast and Lynch Syndrome–Spectrum Cancers DJ Park, K Tao, F Le Calvez-Kelm, T Nguyen-Dumont, N Robinot, ... Cancer discovery 4 (7), 804-815, 2014 | 61 | 2014 |
Prevalence of PALB2 mutations in Australasian multiple-case breast cancer families ZL Teo, DJ Park, E Provenzano, CA Chatfield, FA Odefrey, ... Breast Cancer Research 15, 1-14, 2013 | 56 | 2013 |
Clinical implications of prospective genomic profiling of metastatic breast cancer patients CT van Geelen, P Savas, ZL Teo, SJ Luen, CF Weng, YA Ko, ... Breast Cancer Research 22, 1-13, 2020 | 40 | 2020 |
Mutation screening of PALB2 in clinically ascertained families from the Breast Cancer Family Registry T Nguyen-Dumont, F Hammet, M Mahmoodi, H Tsimiklis, ZL Teo, R Li, ... Breast cancer research and treatment 149, 547-554, 2015 | 29 | 2015 |
Are PALB2 mutations associated with increased risk of male breast cancer? A Sauty de Chalon, Z Teo, DJ Park, FA Odefrey, kConFab, JL Hopper, ... Breast cancer research and treatment 121, 253-255, 2010 | 29 | 2010 |
Intratumoral CD8+ T cells with a tissue-resident memory phenotype mediate local immunity and immune checkpoint responses in breast cancer B Virassamy, F Caramia, P Savas, S Sant, J Wang, SN Christo, A Byrne, ... Cancer Cell 41 (3), 585-601. e8, 2023 | 28 | 2023 |
Integrin linked kinase (ILK) is required for lens epithelial cell survival, proliferation and differentiation ZL Teo, L McQueen-Miscamble, K Turner, G Martinez, B Madakashira, ... Experimental Eye Research 121, 130-142, 2014 | 28 | 2014 |
Tumour morphology predicts PALB2 germline mutation status ZL Teo, E Provenzano, GS Dite, DJ Park, C Apicella, SD Sawyer, ... British journal of cancer 109 (1), 154-163, 2013 | 27 | 2013 |
Oncogene addiction and immunity: clinical implications of tumour infiltrating lymphocytes in breast cancers overexpressing the HER2/neu oncogene P Savas, F Caramia, ZL Teo, S Loi Current opinion in oncology 26 (6), 562-567, 2014 | 25 | 2014 |